Develops engineered proteins and topical live-bacteria treatments for skin diseases in patients with dermatologic conditions.
10-K for FY2025, filed Feb 27, 2026
Its service work is done under a joint development agreement with a research partner, and federal agencies and nonprofit research institutions provide research grants. Azitra has not established a commercial sales or distribution organization.
10-K for FY2025, filed Feb 27, 2026The Company generates service revenue through a joint development agreement with a research partner. The Company recognizes revenue related…View ↗
The Company also generates grant revenue, which represents monies received on contracts with various federal agencies and nonprofit…View ↗
Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We plan to build…View ↗
10-Q for Q3 FY2026, filed Nov 12, 2026
−$2.9MView ↗
Competes with Sixera Pharma, Quoin Pharmaceuticals, Boehringer Ingelheim, Daiichi Sankyo, ResVita Bio, MatriSys, Hoth Therapeutics, Lutris Pharma, and Daewoong Pharmaceutical
10-K for FY2025, filed Feb 27, 2026We are also aware that Sixera Pharma initiated a clinical trial in Europe with SXR-1096, a topical small molecule KLK inhibitor in December…View ↗
Loading...